Licensee fee reduction for manufacturers and wholesalers of medical gas
Summary
SF646 reduces certain Minnesota health-related occupation licensing fees for entities involved in medical gas. Specifically, it lowers the application and annual renewal fees for drug wholesalers and drug manufacturers licensed for medical gases from $5,500 for the first facility plus $500 for each additional facility to $260, while leaving other pharmacy, wholesaler, manufacturer, and controlled-substance fee categories unchanged. The bill also makes conforming changes to the fee-deposit provisions so that the portion of fees directed to the opiate epidemic response fund continues to apply to the affected categories, with the revised fee amounts taking effect the day after final enactment.
The bill amends Minnesota Statutes section 151.065, which governs application fees, annual renewal fees, and the deposit of collected licensing fees. By changing only the medical gas wholesaler and manufacturer fee schedule, it would directly affect businesses that distribute or produce medical gases in Minnesota, reducing their licensing costs and the associated revenue collected by the state from those licenses. The bill does not alter licensure standards, scope of practice, or regulatory oversight beyond the fee adjustments and related deposit language.
Impact
SF646 would amend Minnesota Statutes section 151.065 to lower licensing costs for medical gas wholesalers and manufacturers and to update the statutory references in the fee-deposit provisions. The practical effect is a reduction in state fee revenue from those license categories, while preserving the existing structure that routes specified portions of certain license fees to the state government special revenue fund and the opiate epidemic response fund. It would primarily affect medical gas businesses and the Minnesota Board of Pharmacy/licensing administration.
Sentiment
Based on the bill text and available context, the measure appears to be a targeted, technical fee-reduction bill with no recorded committee debate or votes in the provided materials. The caption and amendments suggest a narrow policy purpose focused on lowering costs for medical gas licensees rather than changing broader health or drug policy. With no transcript or voting history available, there is no documented opposition or support to indicate broader sentiment beyond the bill’s straightforward, administrative nature.
Contention
The main point of potential contention is fiscal: reducing fees for medical gas manufacturers and wholesalers lowers revenue to the state and may modestly affect the amount deposited into the special revenue fund and opiate epidemic response fund. Another possible issue is whether the reduced fees create a special benefit for a narrow set of regulated businesses compared with other licensees who continue to pay substantially higher amounts. No specific objections or supporters are identified in the provided record.